13 GHP Biotechnology & Lifesciences Awards 2025 or over three decades, Altasciences has been dedicated to offering a proven, flexible approach to early-phase drug development to pharmaceutical, biotechnology, and biopharma companies throughout the industry. The company partners with sponsors to help support educated, faster, and more complete early drug development decisions, integrating full-service solutions to safely accelerate development timelines by up to 40%. Altasciences began in 1995 as a clinical research contract research organisation (CRO) and bioanalytical lab focused on generic drug development. However, the company identified a gap in the market. “We saw an opportunity to reimagine early-phase drug development by creating a fully integrated model in which every facet of the process would be united under one organisational roof,” explained Marie-Hélène. After conducting extensive market research that validated this need, Altasciences embarked on a transformative journey starting in 2010, strategically acquiring CROs from across different areas of early-phase drug development, along with a CDMO. Today, the company boasts nine facilities across Canada and the United States, as well as an office in the UK, supporting preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, and formulation and manufacturing. The operation of these services are centralised and supported by communicative teams and systems. Compared to its market peers, Altasciences delivers the only truly integrated, one-stop solution in the early-phase sector. This approach stands out in a competitive market because it removes the need for multiple service providers and centralises scheduling, finance, and overall communication for clients. Key research activities can occur in parallel, rather than sequentially, enabling swift and seamless transitions from one milestone to the next. “At Altasciences, we’ve built a model that safely removes bottlenecks and gatekeepers,” Marie-Hélène told us. “Our goal is simple: to ensure data flows seamlessly and efficiently without compromising quality. We don’t cut corners; we simply remove the inefficiencies to help sponsors get better drugs to the people who need them faster.” A leader in its field, Altasciences has experienced exponential growth over a short period of time, continually increasing its capacity and expanding its comprehensive service offering to consistently meet the industry’s ever-evolving and complex needs. In 2018, the company added its first preclinical safety The conventional development process is unnecessarily fragmented and lengthy. Typically, sponsors must partner with multiple specialist CROs, and in turn, a lot of coordination is needed, often leading to miscommunication and handoffs. But with Altasciences, all aspects of early-phase drug development come together under one roof to provide a more efficient and simplified drug development experience. We found out more from Marie-Hélène Raigneau, President at Altasciences, in the wake of the company’s deserved recognition in the Biotechnology and Lifesciences Awards 2025. Best Biopharmaceutical CRO 2025 testing facility in Seattle to its portfolio, before acquiring more facilities from 2020 to 2023: a manufacturing and formulation company in Philadelphia; a third clinical site in Los Angeles; and three more preclinical facilities in Columbia, Scranton, and Sacramento. In 2023, Altasciences established its first foothold in Europe with an office in the UK dedicated to supporting its European clients. During this period, the company also invested in significant enhancements and expansions to its facilities, completing an expansion to its bioanalytical laboratories in Laval in 2021 and Columbia in 2023. Alongside this, 2023 also saw the construction of a new 53,000-square-foot building at its facility in Philadelphia, complete with a client-dedicated space for Phase 1 through to commercial manufacturing. Driven by a relentless pursuit of excellence, Altasciences has cultivated a team built upon the foundation of respect, quality, integrity, client-centricity, and employee development. These core values empower each member of Altasciences to move in unison, working cross-disciplinarily and collaboratively on projects to tackle challenges and push innovation. This synergy enables Altasciences to maximise opportunities for success and proactively overcome project-specific hurdles, resulting in a seamless and efficient drug development experience for its clientele. “In 2025, Altasciences is celebrating 30 years as a trusted partner in drug development,” Marie-Hélène announced. “Our success stems for one key principle: listening—truly listening— to our clients’ needs today while anticipating what they’ll need tomorrow. Looking ahead, we remain committed to listening, and to exploring new capabilities and technologies that align with current industry needs and international regulations, while continuing to lead the way in novel approaches to early drug development.” Contact Details Contact: Julie-Ann Cabana, Chief Marketing Officer Company: Altasciences Web Address: www.altasciences.com F Feb25169
RkJQdWJsaXNoZXIy NTY1MjM3